Navigation Links
Unigene Comments on FDA Advisory Committee Review of Salmon Calcitonin

BOONTON, N.J., March 6, 2013 /PRNewswire/ -- Unigene Laboratories, Inc. (PINK: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today commented on the outcome of the Food & Drug Administration (FDA) Advisory Committee Meeting held on March 5th, 2013 to discuss whether the benefit of calcitonin salmon for the treatment of postmenopausal osteoporosis outweighs a potential risk of cancer. The Advisory Committee concluded via a 12-9 vote that the benefits of calcitonin products, including Fortical®, do not outweigh the potential risks associated with their use and, as a result, should not continue to be broadly marketed. Unigene is the manufacturer of Fortical Nasal Spray, a calcitonin containing product indicated for the treatment of osteoporosis that is distributed in the USA by Upsher Smith Laboratories, Inc. 

Additionally, the Advisory Committee recommended via a 20-1 vote that fracture prevention data should be required for the approval of new oral calcitonin products in development for osteoporosis prevention and treatment.  This recommendation could impact Unigene's licensee, Tarsa Therapeutics. Tarsa Therapeutics is currently developing an oral calcitonin tablet for the treatment of postmenopausal osteoporosis.

Ashleigh Palmer , Unigene's Chief Executive Officer, stated, "It is our understanding that the FDA will now take the Advisory Committee's recommendations under consideration.  Restricting the use of calcitonin drugs has been a possibility since last year's negative EMA ruling on calcitonin containing products.  Currently, we are evaluating how the specific recommendations from yesterday's Advisory Committee Meeting are likely to affect Unigene.  However, to be clear, they are certain to have a materially adverse impact on the Company's financial situation and operations in the near term. We anticipate being able to provide more details in our upcoming 2012 fourth quarter and year-end update, when we will also discuss other Unigene initiatives and programs not affected by this development."

About Unigene Laboratories, Inc.
Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform.  Peptelligence™ encompasses extensive intellectual property covering drug delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence.  Core Peptelligence™ assets include proprietary oral and nasal peptide drug delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.

Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements, including statements relating to the assessment by the FDA of the recommendations of the Advisory Committee and that the FDA may or may not concur with the Advisory Committee's recommendations, and Unigene's ability to build a robust portfolio of proprietary partnerships in peptide-based therapeutics based on its Peptelligence™ platform. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These known and unknown risk factors include, but are not limited to: the delay in obtaining or the failure to obtain regulatory approvals for our products and the products of our licensees that may generate royalty and milestone payments to us, our ability to achieve product sales and royalties, competition, our dependence on other companies to commercialize, manufacture and sell products using our technologies and our ability to enter into favorable new agreements with such companies, our ability to cut expenses and maintain efficiencies, our ability to enter into new financing arrangements,  the ability of our products to gain market acceptance and increase market share, the uncertainty of results of animal and human testing, the risk of product liability and liability for human clinical trials, our dependence on patents and other proprietary rights and the risks associated with patent litigation, dependence on key management officials, the availability and cost of capital, the availability of qualified personnel, changes in, or the failure to comply with, governmental regulations, general economic and business conditions, our history of losses and ability to achieve profitability, litigation and other risk factors discussed in our Securities and Exchange Commission ("SEC") filings, including our annual report on Form 10-K and our quarterly reports on Form 10-Q. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements. In addition, any statements that refer to expectations, projections, contingencies, goals, targets or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements and are not statements of historical fact. Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we are under no obligation to publicly update or revise any forward-looking statements after the date of this release.

For Investors & Media:
Joshua Drumm , Ph.D. / Jason Rando
Tiberend Strategic Advisors, Inc.
(212) 827-0020

SOURCE Unigene Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Unigene to Announce Fourth Quarter and Full-Year 2011 Financial Results on March 8, 2012
2. Unigene Receives 2012 Drug Delivery Partnerships Industry Achievement Award
3. Unigenes 2011 Year in Review - Key Elements in Place to Address Debt in 2012
4. Unigene to Present at the Oppenheimer 22nd Annual Healthcare Conference on December 13, 2011
5. A New way to Battle Acne? NPR says “Cut the Carbs”: Probiotic Action Comments on the Recent News
6. Probiotic Action Comments on New Findings on Using Light Therapy to Fight Acne
7. Acne Treatment Brand, Probiotic Action, Comments on the Use of a Virus to Treat Acne
8. Probiotic Comments on Claims that Plant-Based Oils Are the Best Acne Treatments
9. Probiotic Action Comments on Huffington Post’s, Best Foods for Acne and offers Advice on Foods to Balance your Body
10. An article from discusses Ban on a Common Acne Treatment; Probiotic Action Comments On the product Ban
11. Can You Be Too Old for Acne? Probiotic Action comments on news from The Vitals Blog
Post Your Comments:
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/25/2015)... , November 26, 2015 ... Biobanking Market 2016 - 2020 report analyzes that ... integrity and quality in long-term samples, minimizing manual ... cost-effectiveness. Automation minimizes manual errors such as mislabeling ... efficiency. Further, it plays a vital role in ...
(Date:11/25/2015)... Studies reveal the differences in species of ... way for more effective treatment for one of the most ... --> --> Gum disease is ... yet relatively little was understood about the bacteria associated with ... by researchers from the WALTHAM Centre for Pet Nutrition together ...
(Date:11/25/2015)... QUEBEC CITY , Nov. 25, 2015 /PRNewswire/ ... "Company"), affirms that its business and prospects remain ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB ... program to completion following review of the final ... met Phase 2 Primary Endpoint in men with ...
Breaking Biology Technology:
(Date:11/20/2015)... , November 20, 2015 NXTD ... focused on the growing mobile commerce market and creator ... Gino Pereira , was recently interviewed on The ... air on this weekend on Bloomberg Europe , ... . --> NXTD ) ("NXT-ID" or the ...
(Date:11/19/2015)... , Nov. 19, 2015  Although some 350 ... is dominated by a few companies, according to Kalorama ... own 51% of the market share of the 6.1 ... The World Market for Molecular Diagnostic s . ... "The market is still controlled by one company and ...
(Date:11/18/2015)... ALBANY, New York , November 18, 2015 /PRNewswire/ ... Transparency Market Research has published a new market report ... Share, Growth, Trends, and Forecast, 2015 - 2021. According to ... bn in 2014 and is anticipated to reach US$29.1 ... 2015 to 2021. North America ...
Breaking Biology News(10 mins):